Vol. 5, No. 076 |
Underwriter: |
|
Resources: |
.gif) |
Finding and Curing Prostate Cancer
In This Issue:
LEAD
- Finding and Curing Prostate Cancer
- Researchers Identify Genetic Pathway Responsible for Metastatic Prostate Cancer
- Scientists Find Key to Hormone-Resistant Prostate Tumors
- New Tool to Help Study Prostate Cancer Developed
WHAT'S NEW AT ZERO
- ZERO Blasts American Cancer Society for Misleading Claims About the PSA Test
- We Need Your Help to Increase Prostate Cancer Research Funding
- Register for the 2010 'Summit to End Prostate Cancer' in Washington, D.C.
- Join the Drive Against Prostate Cancer by Supporting 'Pennies for Prostates'
- 'DASH FOR DAD' Race Series Coming to 11 Cities to Raise Prostate Cancer Awareness
- Register Now to Join the 2010 DASH FOR DAD Team
RESEARCH AND TREATMENT UPDATE
- First Inherited Prostate Cancer Genetic Mutation in African-American Men Identified
- Dietary Supplements Discouraged for Prostate Cancer Patients
- Updated Survival Data on Provenge for Treatment of Hormone Refractory Prostate Cancer Presented
- FDA Approves 6-Month Formulation of Triptorelin Pamoate for Advanced Prostate Cancer
- Roche's Prostate Cancer Drug Fails in a Trial
[Advertisement]
|
Lead
Finding and Curing Prostate Cancer
This primary care physician, explaining how the American Cancer Society "completely missed the boat" on the value of PSA testing, says patients should be screened long before the age of 50.
Researchers Identify Genetic Pathway Responsible for Metastatic Prostate Cancer
Boston researchers identify four genes that together play a direct role in causing metastatic prostate cancer.
Scientists Find Key to Hormone-Resistant Prostate Tumors
Hormone therapy, while proven useful in late-stage prostate cancer, often results in fatal secondary tumors that become resistant to that therapy. Research at USCD indicates a patient's inflammatory response to the therapy may be a factor in creating this resistance.
New Tool to Help Study Prostate Cancer Developed
A new method is developed to better study cells that line and protect the prostate from cancer. Normal cells and cancer cells depend on different factors to survive, according to this Michigan research, and unlike cancer cells, normal secretory cells are not dependent on the male sex hormone androgen for survival.
[Advertisement]
|
What's New at ZERO
ZERO Blasts American Cancer Society for Misleading Claims About the PSA Test
Calling the American Cancer Society a "false prophet" in telling the truth about the effectiveness of the PSA test, ZERO's CEO Skip Lockwood points to documented research showing the PSA test has reduced prostate cancer mortality by 40 percent.
We Need Your Help to Increase Prostate Cancer Research Funding
Write your U.S. SENATORS Today!
 |
||
With the "Dear Colleague Letter" in the House of Representatives now concluded, ZERO needs your help by communicating to your U.S. Senators to emphasize the importance of increasing funding for prostate cancer research.
Senators Tim Johnson (SD) and Mike Crapo (ID) have circulated a letter to their Senate colleagues asking for their support for increased funding for the Prostate Cancer Research Program (PCRP), which is part of the Congressionally Directed Medical Research Program at the Department of Defense.
The program's funding has been stagnant at around $80 million for nine years.
Because of the extended leveling of the program, grants to continue research into clinical trials have slowed to a halt. Unless Congress acts to increase funding for the PCRP, important research cannot move forward to potentially help patients fight their prostate cancer.
Register for the 2010 'Summit to End Prostate Cancer' in Washington, D.C.
 |
||
You can make a positive impact this Fall by representing ZERO and the entire prostate cancer community in Washington, D.C. Registration for the 2010 "Summit to End Prostate Cancer" is now open!
This year's 2010 Summit, scheduled for September 14-16, will focus on effective strategies for increasing the Federal investment in prostate cancer research. During the Summit, participants will have the opportunity to meet with their elected officials on Capitol Hill and learn more about the federal legislative process.
Join the Drive Against Prostate Cancer by Supporting 'Pennies for Prostates'
Now is your chance to take command, sit in the driver's seat, and put the 'pedal to the metal' to show your support for the prostate cancer community.
That's what Robin Sparrow plans to do this April, driving his BMW more than 3,000 miles in 12 days as part of the One Lap of America Race - the "real life" Cannonball Run.
'DASH FOR DAD' Race Series Coming to 11 Cities to Raise Prostate Cancer Awareness
As National Race Series Expands Across U.S. in 2010, Supporters Are Encouraged to Bring This Event to Their City
Lace up your sneakers and join us in the race to end prostate cancer!
DASH FOR DAD, the premier prostate cancer race series in the U.S., is a heartfelt tight-knit community event that brings together athletes, cancer survivors, physicians, caregivers, family members and friends. Proceeds from each 10K race are used to provide free prostate cancer testing for men in the local community of the event.
ZERO - The Project to End Prostate Cancer with sponsors from across the country has grown the DASH FOR DAD and its partner races - the Great Prostate Cancer Challenge - to include 11 cities and an expected 5,000 runners competing in 2010.
The DASH FOR DAD or partnering Great Prostate Cancer Challenge 5K will be held in the following cities during September, known as "National Prostate Cancer Awareness Month":
 |
||
- Baltimore, MD
- Buffalo, NY
- Central FL
- Columbus, OH
- Harrisburg, PA
- Indianapolis, IN
- Kansas City, MO
- Long Island, NY
- Memphis, TN
- Nashville, TN
- Washington, DC metro area (Alexandria, VA)
Since the national race series began in 2008, more than $1 million has been raised to promote prostate cancer awareness, early detection and research. Many runners create teams and collect monetary pledges from family and friends to boost funding for local prostate cancer services.
Hosting a DASH FOR DAD is a significant way to promote prostate cancer awareness in your area - and there is still time to bring this race to your city!
Urology medical practices and other supporting organizations are especially encouraged to organize a DASH FOR DAD, due to the importance of providing free prostate cancer testing and promoting research for a cure. Click here to download the DASH FOR DAD race application.
"DASH FOR DAD elevates prostate cancer awareness to a broader nationwide level," said ZERO's CEO Skip Lockwood. "We all know someone who is impacted by this most commonly diagnosed cancer among men, striking one in every six. That's why we must do all that we can to put an end to this horrible disease."
For more information about the DASH FOR DAD 10K or if you're interested in hosting a DASH FOR DAD run in your neighborhood, contact Tracy Cesaretti.
Register Now to Join 2010 DASH FOR DAD Team
 |
||
Help fight prostate cancer by joining ZERO's DASH FOR DAD Endurance Team!
Even though the team is now complete for the Nautica New York City Triathlon in July, you still have time to sign up to be among the runners on the DASH FOR DAD Endurance Team in the Bank of America Chicago Marathon on October 10, 2010.
These race slots go quickly, so please sign up soon! For more information, contact Tracy Cesaretti at 202-303-3111.
If you're unable to make the Chicago race, you have other options available.
ZERO's DASH FOR DAD Endurance Team for the Marine Corps Marathon in Washington, D.C. is coming on October 24, or you can sign up to participate in the ING New York City Marathon on November 7.
Every dollar raised goes toward free prostate cancer testing for men across the U.S.
ZERO - The Project to End Prostate Cancer provides you with fundraising advice and support, your own donation website and list-serv, and other tools to make your participation in these races highly memorable and successful.
[Advertisement]
|
Research and Treatment Update
First Inherited Prostate Cancer Genetic Mutation in African-American Men Identified
For the first time, research uncovers a genetic mutation in African-American men with a family history of prostate cancer who are at increased risk for the disease.
Dietary Supplements Discouraged for Prostate Cancer Patients
Prostate-specific dietary supplements should not be taken during radiation therapy because they can increase radiosensitivity of normal prostate cells and lead to normal tissue complications, this research shows.
Updated Survival Data on Provenge for Treatment of Hormone Refractory Prostate Cancer Presented
Phase III clinical trial results show the drug Provenge offers a clear survival advantage for men with hormone-refractory prostate cancer.
FDA Approves 6-Month Formulation of Triptorelin Pamoate for Advanced Prostate Cancer
Triptorelin pamoate, marketed as Trelstar, is shown to be longer-acting and effective in reducing testosterone and PSA levels.
Roche's Prostate Cancer Drug Fails in a Trial
Clinical trial results show the drug Avastin did not help men with late-stage prostate cancer live longer.
AWARE Ad Specs
PSA Standardization DVD: